Biohaven (BHVN) Stock Price

Biohaven Price

NYSE·CLOSED
14.48
​
Market closed

The consensus 12-month price target for Biohaven is 13.00 USD, about 10.2% below where the stock trades today. Of 23 analysts, 17 rate the stock a buy — an overall Buy consensus.

Biohaven stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven business model & stock analysis

Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut.

Frequently asked questions about Biohaven

Analysts currently set an average price target of 13.75 USD for the Biohaven stock (median: 13.00 USD), implying -5.0 % versus the latest price. The consensus is based on 23 analyst ratings.

23 analysts currently rate the Biohaven stock: 17 recommend buying, 5 holding and 1 selling. For 2026, analysts expect Biohaven to generate revenue of 2.45 M USD and earnings per share of -2.43 USD.

Converted at the current exchange rate, the Biohaven share trades at 12.92 EUR (14.48 USD).

The Biohaven share (BHVN) is listed on 2 stock exchanges, including: NYSE (BHVN), Frankfurt (2VN.F).

The expected revenue of Biohaven is 2.45 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Biohaven is -292.43 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biohaven is currently -5.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biohaven stock.

The price-to-sales ratio (P/S) of Biohaven is currently 709.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biohaven stock.

The Eulerpool Quality Score for Biohaven is 4/10.

The ISIN of Biohaven is VGG1110E1079. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biohaven is A2DQ7W. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biohaven is BHVN. The ticker symbol is used to trade Biohaven shares on the stock exchange.

Fair ValueTerminal
12.31 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
May 4, 2017
ISIN
VGG1110E1079
Cusip
G11196105
Sedol
BZ8FXC4
Market capitalization
1.32 B USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-5.95
P/Ee 2027
-7.28
P/Ee 2028
-9.07
P/Ee 2029
-15.50
P/Ee 2030
19.15
P/S
P/Se
709.96
EV/EBIT
—
P/B Ratio
25.37
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-248.99 %
Last updated Nov 10, 2026, 3:40 AM

Biohaven Ticker

FRANKFURT · 2VN.FNEW YORK · BHVN

All fundamentals and in-depth analysis of Biohaven

Our stock analysis for Biohaven stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biohaven. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.